Abstract
Genetic Engineering & Biotechnology NewsVol. 32, No. 7 Wall Street Biobeat2012 Has the Makings of a Breakout YearClinical Data, Regulatory Decisions, and M&A Activity Fuel Positive Market SentimentEugene RozelmanEugene RozelmanEugene Rozelman (E-mail Address: erozelman@canaccordgenuity.com) is a principal in the life sciences investment banking sector at Canaccord Genuity (CGI). CGI has received compensation from Amarin, Trimel Pharmaceuticals, and Inhibitex for investment banking activity in the past 12 months.Web: www.canaccordgenuity.com.Search for more papers by this authorPublished Online:31 Mar 2012https://doi.org/10.1089/gen.32.7.06AboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 32Issue 7Apr 2012 Information© 2012 by GEN PublishingTo cite this article:Eugene Rozelman.2012 Has the Makings of a Breakout Year.Genetic Engineering & Biotechnology News.Apr 2012.18-19.http://doi.org/10.1089/gen.32.7.06Published in Volume: 32 Issue 7: March 31, 2012PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
